Mural Oncology Plc (MURA) Live Share Price, Invest From India

Mural Oncology Plc Stock Performance

as on December 5, 2025 at 2:24 am IST

Day's High
$2.03
Day's Price Range
$2.04
$2.03
0.49%
Upside
52 Week's Low
52 Week's High
$0.95
52-Week Price Range
$4.74
$2.03
53.20%
Downside
133.50%
Upside

Mural Oncology Plc share price movements today

Previous Close: $2.04
Open: $2.04
Volume: 341.8K
Day's Low - High: $2.03 - $2.04
52 Week Low - High: $0.95 - $4.74

Mural Oncology Plc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Mural Oncology Plc Stock Fundamentals & Key Indicators

Check Mural Oncology Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

Mural Oncology Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mural Oncology Plc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Mural Oncology Plc	BUY	$-	NA	NA	0.00%
Insmed Incorporated	BUY	$42.0B	393.88%	-16.34	-264.83%
Alnylam Pharmaceuticals, Inc.	BUY	$54.5B	206.63%	1422.86	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$114.3B	101.65%	31.25	31.35%
Regeneron Pharmaceuticals, Inc.	BUY	$79.2B	54.51%	17.42	32.13%

Analyst Recommendation on Mural Oncology Plc Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Mural Oncology Plc. Average target price of $6

Mural Oncology Plc Share Price Target

Get share price movements and forecasts by analysts on Mural Oncology Plc.

What analysts predicted

66.17%UPSIDE

Target Price

Current Price

$2.03

Analyzed by

7 Analysts

Target

$6.00

Mural Oncology Plc target price $6, a slight upside of 66.17% compared to current price of $2.03. According to 7 analysts rating.

Mural Oncology Plc Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	2	-	-	-	3	-	-	-
Gross Profit	-	0	2	0	0	0	0	0	-1	-
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-50	-51	-59	-30	-31	-31	-34	-33	-47	-3
Net Profit Margin	0.00%	0.00%	-2274.10%	0.00%	0.00%	0.00%	-981.50%	0.00%	0.00%	0.00%

Mural Oncology Plc Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-
Gross Profit	-1	-1	-2	-3
Operating Income	-	-	-	-
EBITDA	-	-	-	-
Interest Expense	-	-	-	-
Depreciation	-	-	-	-
Income Before Tax	-	-	-	-
Income Tax Expense	-	-	-	-
Net Income	-175	-189	-207	-128
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

Insights on Mural Oncology Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 170.6% return, outperforming this stock by 220.2%
NEGATIVE IMPACT
Price Dip
In the last 1 year, MURA stock has moved down by -49.6%

About Mural Oncology Plc

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

Organisation	Mural Oncology Plc
E-voting on shares	Click here to vote

FAQs

What is Mural Oncology Plc share price today?

Mural Oncology Plc share price today is $2.03 as on December 5, 2025 at 2:24 am IST at the close of the market. Mural Oncology Plc share today touched a day high of $2.04 and a low of $2.03.

What is the 52 week high and 52 week low for Mural Oncology Plc share?

Mural Oncology Plc share touched a 52 week high of $4.74 on February 7, 2025 and a 52 week low of $0.95 on April 9, 2025. Mural Oncology Plc stock price today i.e. December 5, 2025 at 2:24 am IST is closed at $2.03,which is 57.17% down from its 52 week high and 113.68% up from its 52 week low.

How to invest in Mural Oncology Plc Stock (MURA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mural Oncology Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mural Oncology Plc Shares that will get you 0.7389 shares as per Mural Oncology Plc share price of $2.03 per share as on December 5, 2025 at 2:24 am IST.

What is the minimum amount required to buy Mural Oncology Plc Stock (MURA) from India?

Indian investors can start investing in Mural Oncology Plc (MURA) shares with as little as ₹90.544 or $1 (as of December 14, 2025 at 7:12 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹905.44 in Mural Oncology Plc stock (as per the Rupee-Dollar exchange rate as on December 14, 2025 at 7:12 am IST). Based on Mural Oncology Plc share’s latest price of $2.03 as on December 5, 2025 at 2:24 am IST, you will get 4.9261 shares of Mural Oncology Plc. Learn more about fractional shares .